Arilan Dosage/Direction for Use

Dosage: Adults: Schizophrenia: The recommended starting dose for aripiprazole is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.
Aripiprazole is effective in a dose range of 10 to 30 mg/day.
Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.
Manic episodes in Bipolar I Disorder: The recommended starting dose for aripiprazole is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see Pharmacology: Pharmacodynamics under Actions). Some patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.
Recurrence prevention of manic episodes in Bipolar I Disorder: For preventing recurrence of manic episodes in patients who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose. Adjustments of daily dose, including dose reduction should be considered on the basis of clinical status.
Paediatric population: Schizophrenic in adolescents aged 15 years and older: The recommended dose for aripiprazole is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using an appropriate aripiprazole containing medicinal product) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see Pharmacology: Pharmacodynamics under Actions).
Aripiprazole is effective in a dose range of 10 to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated although individual patients may benefit from a higher dose.
Aripiprazole is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see Adverse Reactions and Pharmacology: Pharmacodynamics under Actions).
Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older: The recommended dose for aripiprazole is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using an appropriate aripiprazole containing medicinal product) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg.
The treatment duration should be the minimum necessary for symptom control and must not exceed 12 weeks. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg reactions including EPS related events, somnolence, fatigue and weight gain (see Adverse Reactions). Doses higher than 10 mg/day should therefore only be used in exceptional cases and with close clinical monitoring (see Precautions, Adverse Reactions and Pharmacology: Pharmacodynamics under Actions).
Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Therefore, aripiprazole is not recommended for use in patients below 13 years of age (see Adverse Reactions and Pharmacology: Pharmacodynamics under Actions).
Irritability associated with autistic disorder: The safety and efficacy of aripiprazole in children and adolescents aged below 18 years have not been established. Currently available data are described in Pharmacology: Pharmacodynamics under Actions but no recommendation on a dosage can be made.
Tics associated with Tourette's disorder: The safety and efficacy of aripiprazole in children and adolescents 6 to 18 years of age have not yet been established. Currently available data are described in Pharmacology: Pharmacodynamics under Actions but no recommendation on a posology can be made.
Special Population Hepatic impairment: No dose adjustment is required for patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Renal impairment: No dose adjustment is required in patients with renal impairment.
Elderly: The safety and efficacy of aripiprazole in the treatment of schizophrenia or manic episodes in Bipolar I Disorder in patients aged 65 years and older has not been established. Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant (see Precautions).
Gender: No dose equivalent is required for female patients as compared to male patients (see Pharmacology: Pharmacokinetics under Actions).
Smoking status: According to the metabolic pathway of aripiprazole no dose adjustment is required for smokers (see Interactions).
Dose adjustments due to interactions: When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased (see Interactions).
When concomitant administration of strong CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the combination therapy, the aripiprazole dose should then be reduced to the recommended dose (see Interactions).
Method of administration: Aripiprazole tablets are for oral use.